康灃生物中期業績創紀錄 呼吸介入產品驅動收入激增162% Cryofocus Medtech (Shanghai) Co., Ltd. Aug 11, 2025 10:41 HKT/SGT Read More
云顶新耀耐赋康(R)扩产获批 亚洲全域完全批准双突破 加速迈向50亿销售峰值 Everest Medicines Limited Aug 08, 2025 18:09 HKT/SGT Read More
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan Everest Medicines Limited Aug 08, 2025 18:09 HKT/SGT Read More
雲頂新耀耐賦康(R)擴產獲批 亞洲全域完全批准雙突破 加速邁向50億銷售峰值 Everest Medicines Limited Aug 08, 2025 18:09 HKT/SGT Read More
Cornerstone Robotics Completes the World's First Clinical Validation of Autonomous Surgery Performed by Robot-Assisted Surgery Cornerstone Robotics Aug 06, 2025 19:21 HKT/SGT Read More
TruMerit Launches Global Credential for First-Level, General Nurses TruMerit Aug 06, 2025 09:00 HKT/SGT Read More
NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
全球首個IgA腎病對因治療藥物耐賦康®擴產獲批 雲頂新耀加速提升可及性與產能佈局 Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
全球首个IgA肾病对因治疗药物耐赋康®扩产获批 云顶新耀加速提升可及性与产能布局 Everest Medicines Limited Aug 05, 2025 10:21 HKT/SGT Read More
旅行者醫療支援平台 Traveler Care 正式全球上線,協助旅遊保險公司減少 80% 急診索賠 Traveler Care Aug 04, 2025 23:00 HKT/SGT Read More
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80% Traveler Care Aug 04, 2025 21:00 HKT/SGT Read More
Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies Everest Medicines Limited Aug 02, 2025 00:02 HKT/SGT Read More
雲頂新耀宣佈增加對I-Mab的戰略投資 開發自研新一代腫瘤免疫療法的全球價值 Everest Medicines Limited Aug 01, 2025 23:48 HKT/SGT Read More
云顶新耀宣布增加对I-Mab的战略投资 开发自研新一代肿瘤免疫疗法的全球价值 Everest Medicines Limited Aug 01, 2025 23:45 HKT/SGT Read More
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC Eisai Jul 31, 2025 08:30 HKT/SGT Read More
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease Eisai Jul 31, 2025 08:20 HKT/SGT Read More